Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kreissl, S.; Goergen, H.; Buehnen, I.; Kobe, C.; Moccia, A.; Greil, R.; Eichenauer, D.A.; Zijlstra, J.M.; Markova, J.; Meissner, J.; et al. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): Follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021, 8, e398–e409. [Google Scholar] [CrossRef] [PubMed]
- Demeestere, I.; Racape, J.; Dechene, J.; Dupuis, J.; Morschhauser, F.; De Wilde, V.; Lazarovici, J.; Ghesquieres, H.; Touati, M.; Sibon, D.; et al. Gonadal Function Recovery in Patients with Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011). J. Clin. Oncol. 2021, 39, 3251–3260. [Google Scholar] [CrossRef]
- Anderson, R.A.; Remedios, R.; Kirkwood, A.A.; Patrick, P.; Stevens, L.; Clifton-Hadley, L.; Roberts, T.; Hatton, C.; Kalakonda, N.; Milligan, D.W.; et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin’s lymphoma (RATHL): A secondary analysis of a randomised phase 3 trial. Lancet Oncol. 2018, 19, 1328–1337. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stephens, D.M.; Li, H.; Schöder, H.; Straus, D.J.; Moskowitz, C.H.; LeBlanc, M.; Rimsza, L.M.; Bartlett, N.L.; Evens, A.M.; LaCasce, A.S.; et al. Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019, 134, 1238–1246. [Google Scholar] [CrossRef]
- Skoetz, N.; Will, A.; Monsef, I.; Brillant, C.; Engert, A.; von Tresckow, B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst. Rev. 2017, 5, CD007941. [Google Scholar] [CrossRef]
- Johnson, P.; Federico, M.; Kirkwood, A.; Fossa, A.; Berkahn, L.; Carella, A.M.; d’Amore, F.; Enblad, G.; Franceschetto, A.; Fulham, M.; et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N. Engl. J. Med. 2016, 374, 2419–2429. [Google Scholar] [CrossRef]
- Hutchings, M.; Loft, A.; Hansen, M.; Pedersen, L.M.; Buhl, T.; Jurlander, J.; Buus, S.; Keiding, S.; D’Amore, F.; Boesen, A.-M.; et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107, 52–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gallamini, A.; Rigacci, L.; Merli, F.; Nassi, L.; Bosi, A.; Capodanno, I.; Luminari, S.; Vitolo, U.; Iannitto, E.; Trentin, L.; et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 2006, 91, 475–481. [Google Scholar] [PubMed]
- Biggi, A.; Gallamini, A.; Chauvie, S.; Hutchings, M.; Kostakoglu, L.; Gregianin, M.; Meignan, M.; Malkowski, B.; Hofman, M.S.; Barrington, S.F. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J. Nucl. Med. 2013, 54, 683–690. [Google Scholar] [CrossRef] [Green Version]
- Zinzani, P.L.; Broccoli, A.; Gioia, D.M.; Castagnoli, A.; Ciccone, G.; Evangelista, A.; Santoro, A.; Ricardi, U.; Bonfichi, M.; Brusamolino, E.; et al. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J. Clin. Oncol. 2016, 34, 1376–1385. [Google Scholar] [CrossRef]
- Oki, Y.; Chuang, H.; Chasen, B.; Jessop, A.; Pan, T.; Fanale, M.; Dabaja, B.; Fowler, N.; Romaguera, J.; Fayad, L.; et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br. J. Haematol. 2014, 165, 112–116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Straus, D.J.; Długosz-Danecka, M.; Alekseev, S.; Illés, Á.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K.L.; Bartlett, N.L.; et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020, 135, 735–742. [Google Scholar] [CrossRef]
- Novo, M.; Nowakowski, G.S.; Habermann, T.M.; Witzig, T.E.; Micallef, I.N.; Johnston, P.B.; Inwards, D.J.; Botto, B.; Ristow, K.M.; Young, J.R.; et al. Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: Biopsy, treat or observe? Leuk. Lymphoma 2020, 61, 318–327. [Google Scholar] [CrossRef]
- Schaefer, N.G.; Taverna, C.; Strobel, K.; Wastl, C.; Kurrer, M.; Hany, T.F. Hodgkin disease: Diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Radiology 2007, 244, 257–262. [Google Scholar] [CrossRef] [PubMed]
- de Wit, M.; Bohuslavizki, K.H.; Buchert, R.; Bumann, D.; Clausen, M.; Hossfeld, D.K. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann. Oncol. 2001, 12, 29–37. [Google Scholar] [CrossRef] [PubMed]
- Kobe, C.; Dietlein, M.; Hellwig, D. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Semin. Nucl. Med. 2018, 48, 28–36. [Google Scholar] [CrossRef]
- Spina, V.; Bruscaggin, A.; Cuccaro, A.; Martini, M.; Di Trani, M.; Forestieri, G.; Manzoni, M.; Condoluci, A.; Arribas, A.; Terzi-Di-Bergamo, L.; et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018, 131, 2413–2425. [Google Scholar] [CrossRef] [Green Version]
- Biggi, A.; Bergesio, F.; Chauvie, S. Monitoring response in lymphomas: Qualitative, quantitative, or what else? Leuk. Lymphoma 2019, 60, 302–308. [Google Scholar] [CrossRef]
- Hasenclever, D.; Kurch, L.; Mauz-Körholz, C.; Elsner, A.; Georgi, T.; Wallace, H.; Landman-Parker, J.; Moryl-Bujakowska, A.; Cepelová, M.; Karlén, J.; et al. qPET—A quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1301–1308. [Google Scholar] [CrossRef]
- Hasenclever, D.; Diehl, V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N. Engl. J. Med. 1998, 339, 1506–1514. [Google Scholar] [CrossRef]
- Connors, J.M.; Jurczak, W.; Straus, D.J.; Ansell, S.M.; Kim, W.S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illés, Á.; Picardi, M.; et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N. Engl. J. Med. 2018, 378, 331–344. [Google Scholar] [CrossRef] [PubMed]
- Cerci, J.J.; Pracchia, L.F.; Linardi, C.C.; Pitella, F.A.; Delbeke, D.; Izaki, M.; Trindade, E.; Soares, J.; Buccheri, V.; Meneghetti, J.C. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J. Nucl. Med. 2010, 51, 1337–1343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zinzani, P.L.; Rigacci, L.; Stefoni, V.; Broccoli, A.; Puccini, B.; Castagnoli, A.; Vaggelli, L.; Zanoni, L.; Argnani, L.; Baccarani, M.; et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: Evaluation on 304 patients. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 4–12. [Google Scholar] [CrossRef]
- Hamid, M.S.; Rutherford, S.C.; Jang, H.; Kim, S.; Patel, K.; Bartlett, N.L.; Malecek, M.K.; Watkins, M.P.; Maddocks, K.J.; Bond, D.A.; et al. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clin. Lymphoma Myeloma Leuk. 2022, 22, e435–e442. [Google Scholar] [CrossRef]
- Picardi, M.; Fonti, R.; Della Pepa, R.; Giordano, C.; Pugliese, N.; Nicolai, E.; Salvatore, M.; Mainolfi, C.; Venetucci, P.; Rascato, M.G.; et al. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma. Eur. J. Cancer 2020, 132, 85–97. [Google Scholar] [CrossRef]
- Barrington, S.F.; Kluge, R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur. J. Nucl. Med. Mol. Imaging 2017, 44 (Suppl. 1), 97–110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Annunziata, S.; Cuccaro, A.; Calcagni, M.L.; Hohaus, S.; Giordano, A.; Rufini, V. Interim FDG-PET/CT in Hodgkin lymphoma: The prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann. Nucl. Med. 2016, 30, 588–592. [Google Scholar] [CrossRef] [PubMed]
- Toledano, M.N.; Vera, P.; Tilly, H.; Jardin, F.; Becker, S. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio. PLoS ONE 2019, 14, e0211649. [Google Scholar] [CrossRef]
- Gallamini, A.; Tarella, C.; Viviani, S.; Rossi, A.; Patti, C.; Mulé, A.; Picardi, M.; Romano, A.; Cantonetti, M.; La Nasa, G.; et al. Early Chemotherapy Intensification with Escalated BEACOPP in Patients with Advanced-Stage Hodgkin Lymphoma with a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. J. Clin. Oncol. 2018, 36, 454–462. [Google Scholar] [CrossRef]
- Moskowitz, A.J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; et al. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J. Clin. Oncol. 2021, 39, 3109–3117. [Google Scholar] [CrossRef]
- Picardi, M.; Della Pepa, R.; Giordano, C.; Pugliese, N.; Mortaruolo, C.; Trastulli, F.; Rascato, M.G.; Cappuccio, I.; Raimondo, M.; Memoli, M.; et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 2019, 3, 1546–1552. [Google Scholar] [CrossRef] [PubMed]
- Amitai, I.; Gurion, R.; Vidal, L.; Dann, E.J.; Raanani, P.; Gafter-Gvili, A. PET-adapted therapy for advanced Hodgkin lymphoma—Systematic review. Acta Oncol. 2018, 57, 765–772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Characteristic | All | qPET2− | qPET2+ | EscBEACOPP † | p * |
---|---|---|---|---|---|
No. of patients | 227 | 170 | 48 | 9 | |
Median age (range), years | 34 [18; 87] | 34 [18; 82] | 35.0 [19; 87] | 32.0 [19; 59] | 0.66 |
Age ≥ 45 | 57 (25%) | 41 (24%) | 13 (27%) | 3 (33%) | 0.82 |
Female sex | 115 (51%) | 87 (51%) | 24 (50.0%) | 4 (44%) | 0.99 |
ECOG > 1 | 6 (3%) | 3 (2%) | 3 (6%) | 0 (0%) | 0.12 |
Ann Arbor Stage | 0.12 | ||||
II-U | 52 (23%) | 39 (23%) | 10 (21%) | 3 (33%) | |
II-X | 12 (5%) | 6 (4%) | 5 (10%) | 1 (11%) | |
III | 83 (37%) | 68 (40%) | 13 (27%) | 2 (22%) | |
IV | 80 (35%) | 57 (34%) | 20 (42%) | 3 (33%) | |
IPS score | 0.004 | ||||
0–3 | 201 (89%) | 158 (93%) | 37 (77%) | 6 (67%) | |
4–7 | 26 (12%) | 12 (7%) | 11 (23%) | 3 (33%) | |
Extranodal Involvement | 87 (38%) | 61 (36%) | 23 (48%) | 3 (33%) | 0.18 |
Bulk | 29 (13%) | 18 (11%) | 7 (15%) | 4 (44%) | 0.61 |
Response (chemotherapy) | |||||
CR | 194 (86%) | 159 (94%) | 31 (65%) | 4 (44%) | <0.001 |
PR | 12 (5%) | 1 (1%) | 9 (19%) | 2 (22%) | |
POD | 19 (8%) | 9 (5%) | 7 (15%) | 3 (33%) | |
TRM | 2 (1%) | 1 (1%) | 1 (2%) | 0 (0%) | |
Radiotherapy | 21 (9%) | 10 (6%) | 7 (15%) | 4 (44%) | 0.07 |
Pts. | PFS | OS | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Events | Median Survival | 3-Year PFS | HR | p | Events | Median Survival | 5-Year OS | HR | p | ||
LLS * | |||||||||||
qPET2− | 170 | 25 | NR | 0.88 [0.83; 0.93] | 1.0 | 6 | NR [NR; NR] | 0.96 [0.93; 1.0] | 1.0 | 1.0 | |
qPET2+ | 48 | 15 | NR | 0.70 [0.58; 0.85] | 2.62 [1.38:4.97] | <0.001 | 4 | 102 [86; NR] | 0.98 [0.94; 1.0] | 2.61 [0.73:9.31] | 0.14 |
Deauville † | |||||||||||
dvPET2− | 195 | 32 | NR | 0.86 [0.82; 0.91] | 1.0 | 7 | NA [102; NR] | 0.97 [0.94; 1.0] | 1.0 | 1.0 | |
dvPET2+ | 23 | 8 | NR | 0.64 [0.47; 0.88] | 2.65 [1.22:5.77] | 0.01 | 3 | 86 [79; NR] | 0.96 [0.88; 1.0] | 6.15 [1.46:25.96] | 0.01 |
escBEACOPP § | 9 | 5 | 39 [10; NR] | 0.56 [0.31; 1.0] | 4.53 [1.76:11.68] | <0.001 | 0 | NR [NR; NR] | 1.0 [1.0; 1.0] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C.L.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.J.; et al. Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting. Cancers 2023, 15, 1760. https://doi.org/10.3390/cancers15061760
Zheng S, Gupta K, Goyal P, Nakajima R, Michaud L, Batlevi CL, Hamlin PA, Horwitz S, Kumar A, Matasar MJ, et al. Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting. Cancers. 2023; 15(6):1760. https://doi.org/10.3390/cancers15061760
Chicago/Turabian StyleZheng, Serena, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A. Hamlin, Steven Horwitz, Anita Kumar, Matthew J. Matasar, and et al. 2023. "Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting" Cancers 15, no. 6: 1760. https://doi.org/10.3390/cancers15061760